Description

Envarsus (tacrolimus) tablets with prolonged release 0.75 mg. №30

Ingredients

Each tablet contains 0.75 mg of tacrolimus.

Dosage

The recommended dosage is determined by a healthcare provider based on individual factors.

Indications

Envarsus tablets are indicated for the prophylaxis of organ rejection in adult kidney or liver transplant patients.

Contraindications

Do not use Envarsus if you are allergic to tacrolimus or any of the ingredients in the formulation.

Directions

Take Envarsus exactly as prescribed by your healthcare provider. Do not crush or chew the tablets.

Scientific Evidence

Tacrolimus, the active ingredient in Envarsus, is a calcineurin inhibitor that suppresses the immune system to prevent organ rejection in transplant patients. The prolonged-release formulation of Envarsus offers a more consistent drug level in the blood, reducing the frequency of dosing and potentially improving patient adherence to the treatment regimen.

Studies have shown that tacrolimus-based regimens, including Envarsus, are effective in preventing organ rejection with a lower incidence of adverse effects compared to other immunosuppressants. Research published in the American Journal of Transplantation demonstrated the efficacy and safety of prolonged-release tacrolimus in kidney transplant recipients.

Additional Information

It is important to monitor tacrolimus blood levels regularly to ensure therapeutic efficacy and minimize the risk of toxicity. Envarsus tablets should be stored at room temperature away from moisture and heat.

Consult your healthcare provider for specific dosing instructions and any concerns about potential drug interactions. Inform your doctor about all medications, vitamins, and supplements you are taking before starting Envarsus therapy.